ProxyDISCOVERY
Patient-Relevant Models for Drug Discovery
Delivering organoid-based insights to improve predictions, reduce risk, and accelerate therapies from the lab to the clinic.
THE CHALLENGE
Traditional drug development relies on simple models that often fail to accurately predict human response
This gap drives high rates of late-stage trial failure, wasted investment, and delayed treatments for patients.
ProxyDISCOVERY
Human Biology at the Core
ProxyDiscovery provides patient-derived organoid models that mirror real tumor biology. By generating functional readouts of drug response, we enable more accurate predictions of clinical outcomes and guide better decision-making at every stage of discovery.
High-throughput screening
Our 96- and 384-well automated platforms enable large-scale screening of thousands of compounds across diverse patient-derived organoids. With real-time monitoring and data collection, we rapidly identify promising leads, accelerating discovery with both scale and precision.
Target validation and hit-to-lead discovery
Using patient-derived organoids, we validate drug targets and identify compounds with the greatest likelihood of success. By prioritizing leads based on organoid response data and filtering out false positives from traditional models, we streamline the transition from discovery to development with higher confidence.
Lead optimization, validation, and IND-enabling
We test lead compounds across diverse patient populations to capture variability in response. Through predictive modeling of therapeutic windows and safety profiles, we help identify patient subgroups most likely to benefit, reducing risk and improving outcomes.
Clinical trial support
(phase I–III)
We enable smarter clinical trial design through patient stratification, biomarker identification, and companion diagnostic development. By enriching trial populations and predicting likely responders, we help increase trial efficiency and improve the probability of clinical success.
Transforming Development
We help partners cut clinical trial failures, saving hundreds of millions per compound while accelerating time to market. Through collaborative research, licensing, and co-development, we provide access to world-class organoid expertise, predictive analytics, and diverse patient populations.
From early discovery through clinical trials, ProxyDiscovery delivers the clarity needed to reduce risk and improve outcomes.